万赛维上市时间

The tablet is the L-valyl ester (prodrug) of ganciclovir, which is rapidly converted into ganciclovir by esterases in the small intestine and liver after oral administration. Ganciclovir is a synthetic 2’-deoxyguanosine monophosphate analog that inhibits herpesvirus replication in vitro and in vivo. Susceptible human viruses include human cytomegalovirus (HCMV), herpes simplex virus-1 and herpes simplex virus-2 (HSV-1, HSV-2), human herpesvirus-6, 7, 8 (HHV-6, 7, 8), Epstein-Barr virus, varicella-zoster virus (VZV), and hepatitis B virus.

When will Vansavi be launched?

In May 2001, the US FDA approved the market. Valcyte is clinically used to treat acute retinitis caused by CMV infection in patients with acquired immunodeficiency syndrome. In May 2003, its indications were expanded. Valcyte is used to prevent and treat secondary CMV infection in organ transplant recipients. It was launched in China in 2006. Its indications are induction treatment of CMV retinitis, maintenance treatment of CMV retinitis and prevention of CMV infection in transplant patients.

On August 11, 2010, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) approved Valcyte for the treatment of adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.

Note: The tablet is a prodrug of ganciclovir, which is rapidly converted into ganciclovir after oral administration and needs to be taken with food. Blood images need to be monitored during medication; discontinue the medication or add G-CSF if the peripheral blood neutrophil count is <500/μL; consider discontinuing the medication if the peripheral blood platelet count is <25 000/μL or hemoglobin <80g/L; those with central nervous system side effects should avoid driving cars and operating machinery.